Synthetic biology play Senti debuts with $53M series A

Senti Biosciences Inc. (South San Francisco, Calif.) announced a tranched $53 million series A round led by existing investor New Enterprise

Read the full 211 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE